WuXi PharmaTech to Establish Largest Drug Outsourc

97c69vin68jh

WuXi PharmaTech (WX.NYSE) has signed an agreement to establish a biopharmaceutical company in Wuxi,[link widoczny dla zalogowanych], of eastern China's Jiangsu province.
The new firm,[link widoczny dla zalogowanych], located in the Wuxi Outsourcing Area for Bio-Medical Research and Development, boasts a registered capital of 100 million yuan, and covers an area of about 6.7 hectares.
The firm will be built according to advance international standards. It will use the proprietary technology and human resources of its parent company WuXi PharmaTech to provide biopharmaceutical R&D and manufacturing outsourcing services which include exporting monoclonal antibodies,[link widoczny dla zalogowanych], vaccines,[link widoczny dla zalogowanych], and recombinant proteins to global biopharmaceutical companies.
After the new company enters into production, its annual revenue will reach around 200 million yuan.
WuXi PharmaTech is a pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the US. In January 2008,[link widoczny dla zalogowanych], the company completed its acquisition of AppTec Laboratory Services.
For full details on Wuxi Pharmatech Cayman Inc (WX) click here. Wuxi Pharmatech Cayman Inc (WX) has Short Term PowerRatings of 4. Details on Wuxi Pharmatech Cayman Inc (WX) Short Term PowerRatings is available at This Link.